147 related articles for article (PubMed ID: 15899835)
41. Loss of multidrug resistance protein 1 expression and folate efflux activity results in a highly concentrative folate transport in human leukemia cells.
Assaraf YG; Rothem L; Hooijberg JH; Stark M; Ifergan I; Kathmann I; Dijkmans BA; Peters GJ; Jansen G
J Biol Chem; 2003 Feb; 278(9):6680-6. PubMed ID: 12486126
[TBL] [Abstract][Full Text] [Related]
42. Antifolate resistance mediated by the multidrug resistance proteins MRP1 and MRP2.
Hooijberg JH; Broxterman HJ; Kool M; Assaraf YG; Peters GJ; Noordhuis P; Scheper RJ; Borst P; Pinedo HM; Jansen G
Cancer Res; 1999 Jun; 59(11):2532-5. PubMed ID: 10363967
[TBL] [Abstract][Full Text] [Related]
43. Cellular aspects of folate and antifolate membrane transport.
Brzezińska A; Wińska P; Balińska M
Acta Biochim Pol; 2000; 47(3):735-49. PubMed ID: 11310973
[TBL] [Abstract][Full Text] [Related]
44. Interaction of methotrexate with organic-anion transporting polypeptide 1A2 and its genetic variants.
Badagnani I; Castro RA; Taylor TR; Brett CM; Huang CC; Stryke D; Kawamoto M; Johns SJ; Ferrin TE; Carlson EJ; Burchard EG; Giacomini KM
J Pharmacol Exp Ther; 2006 Aug; 318(2):521-9. PubMed ID: 16702441
[TBL] [Abstract][Full Text] [Related]
45. Expression and localization of the multidrug resistance protein 5 (MRP5/ABCC5), a cellular export pump for cyclic nucleotides, in human heart.
Dazert P; Meissner K; Vogelgesang S; Heydrich B; Eckel L; Böhm M; Warzok R; Kerb R; Brinkmann U; Schaeffeler E; Schwab M; Cascorbi I; Jedlitschky G; Kroemer HK
Am J Pathol; 2003 Oct; 163(4):1567-77. PubMed ID: 14507663
[TBL] [Abstract][Full Text] [Related]
46. Methotrexate transport and resistance.
Moscow JA
Leuk Lymphoma; 1998 Jul; 30(3-4):215-24. PubMed ID: 9713954
[TBL] [Abstract][Full Text] [Related]
47. A molecular model of a putative substrate releasing conformation of multidrug resistance protein 5 (MRP5).
Ravna AW; Sylte I; Sager G
Eur J Med Chem; 2008 Nov; 43(11):2557-67. PubMed ID: 18313803
[TBL] [Abstract][Full Text] [Related]
48. The membrane transport and polyglutamation of pralatrexate: a new-generation dihydrofolate reductase inhibitor.
Visentin M; Unal ES; Zhao R; Goldman ID
Cancer Chemother Pharmacol; 2013 Sep; 72(3):597-606. PubMed ID: 23881211
[TBL] [Abstract][Full Text] [Related]
49. Computer modelling of antifolate inhibition of folate metabolism using hybrid functional petri nets.
Assaraf YG; Ifergan I; Kadry WN; Pinter RY
J Theor Biol; 2006 Jun; 240(4):637-47. PubMed ID: 16352313
[TBL] [Abstract][Full Text] [Related]
50. Distribution and functional activity of P-glycoprotein and multidrug resistance-associated proteins in human brain microvascular endothelial cells in hippocampal sclerosis.
Kubota H; Ishihara H; Langmann T; Schmitz G; Stieger B; Wieser HG; Yonekawa Y; Frei K
Epilepsy Res; 2006 Mar; 68(3):213-28. PubMed ID: 16361082
[TBL] [Abstract][Full Text] [Related]
51. Enhanced systemic availability of methotrexate in the presence of morin in rats.
Hong SS; Jin MJ; Han HK
Biopharm Drug Dispos; 2008 May; 29(4):189-93. PubMed ID: 18240155
[TBL] [Abstract][Full Text] [Related]
52. Mistletoe lectin binds to multidrug resistance-associated protein MRP5.
Nehmann N; Schade UM; Pfüller U; Schachner M; Schumacher U
Anticancer Res; 2009 Dec; 29(12):4941-8. PubMed ID: 20044600
[TBL] [Abstract][Full Text] [Related]
53. Methotrexate induction of human sulfotransferases in Hep G2 and Caco-2 cells.
Chen X; Baker SM; Chen G
J Appl Toxicol; 2005; 25(5):354-60. PubMed ID: 15986412
[TBL] [Abstract][Full Text] [Related]
54. Impairment of methotrexate (MTX)-polyglutamate formation of MTX-resistant K562 cell lines.
Koizumi S
Jpn J Cancer Res; 1988 Nov; 79(11):1230-7. PubMed ID: 2465288
[TBL] [Abstract][Full Text] [Related]
55. Characterization of binding of folates and antifolates to brush-border membrane vesicles isolated from human kidney.
Damaraju VL; Hamilton KF; Seth-Smith ML; Cass CE; Sawyer MB
Mol Pharmacol; 2005 Feb; 67(2):453-9. PubMed ID: 15509714
[TBL] [Abstract][Full Text] [Related]
56. Down regulation of multidrug resistance protein-1 expression in patients with early rheumatoid arthritis exposed to methotrexate as a first disease-modifying antirheumatic drug.
Hider SL; Owen A; Hartkoorn R; Khoo S; Back D; Silman AJ; Bruce IN
Ann Rheum Dis; 2006 Oct; 65(10):1390-3. PubMed ID: 16504991
[TBL] [Abstract][Full Text] [Related]
57. Methotrexate and aminopterin lack in vivo antimalarial activity against murine malaria species.
Irungu B; Kiboi D; Langat B; Rukunga G; Wittlin S; Nzila A
Exp Parasitol; 2009 Oct; 123(2):118-21. PubMed ID: 19527714
[TBL] [Abstract][Full Text] [Related]
58. Sepsis affects cardiac expression of multidrug resistance protein 5 (MRP5, ABCC5), an ABC-type CGMP export pump.
Meissner K; Kessler W; Meyer zu Schwabedissen HE; Schuster K; Saalfeld K; Grube M; Buck A; Jedlitschky G; Maier S; Traeger T; Mostertz J; Homuth G; Heidecke CD; Lehmann C; Kroemer HK
Shock; 2007 Nov; 28(5):564-9. PubMed ID: 17589384
[TBL] [Abstract][Full Text] [Related]
59. Evidence for the facilitated transport of methotrexate polyglutamates into lysosomes derived from S180 cells. Basic properties and specificity for polyglutamate chain length.
Barrueco JR; Sirotnak FM
J Biol Chem; 1991 Jun; 266(18):11732-7. PubMed ID: 1711038
[TBL] [Abstract][Full Text] [Related]
60. Immunolocalization of multidrug resistance protein 5 in the human genitourinary system.
Nies AT; Spring H; Thon WF; Keppler D; Jedlitschky G
J Urol; 2002 May; 167(5):2271-5. PubMed ID: 11956491
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
